8 results about "Cystatin C" patented technology

The present invention provides a method for detecting the presence of or risk of bladder cancer in a female patient, the method comprising the steps of: detecting the presence of a biomarker panel in a sample isolated from a female patient, the biomarker panel comprising IL-13 and IL-12p70 and one or more biomarkers selected from the group consisting of BTA, midkine, PAI-1 / tPA, 8OHdG, CEA, CK18, Fibrillin, Creatinine, CXCL16, Cystatin B, Cystatin C, d-dimer, EGF, FAS, HAD, IL-1a, IL-1b, IL-4, IL-6, IL-7, IL-8, MCP-1, Microalbumin, MMP9 NGAL, MMP9 TIMP1, NGAL, NSE, Progranulin, TUP, TGFB1, Thrombomodulin, sTNFR1, TPA, VEGF and Triglyceride, and / or the concentration of albumin / microalbumin / protein to creatinine in a sample isolated from a female patient, expressed as an albumin:creatinine ratio; and assessing the result and comparing it to a normal control, wherein an increase in the presence of the biomarkers compared to the normal control indicates the presence or risk of cancer in the patient from which the sample was isolated.

Identifying the causes of haematuria requires detailed clinical investigations. Unbalanced patient populations (mostly male) and diverse causes complicate patient classification and biomarker identification. Multi-marker analysis with advanced methods can improve diagnosis even in unbalanced datasets. We used k-means clustering, decision trees, random forest with LIME explainer, and CACTUS algorithm to classify patients as healthy (with no clear cause of haematuria) or sick (with an identified cause of haematuria e.g., bladder cancer, or infection). The CACTUS algorithm was more robust to dataset imbalance, achieving balanced accuracy of 0.747 for both genders, 0.718 for females, and 0.803 for males. Key biomarkers identified included microalbumin, male gender, and tPSA for the whole dataset; age, microalbumin, tPSA, cystatin C, BTA, HAD, and S100A4 for males; and microalbumin, IL-8, pERK, and CXCL16 for females. CACTUS outperformed decision trees and random forest, highlighting potential novel biomarkers for future diagnosis.

The application discloses an application of an RNF130 activator in preparation of a medicine for preventing and / or treating acute kidney injury, and belongs to the technical field of biological medicines.The application provides an application of the RNF130 activator in preparation of a medicine for preventing or treating kidney ischemia-reperfusion injury, and the RNF130 activator can improve kidney function of a mouse with kidney ischemia-reperfusion injury, improve levels of blood creatinine, urea nitrogen and cystatin C, reduce levels of kidney injury markers KIM-1 and LCN2, and reduce tubular injury, thereby playing a preventive and therapeutic role on kidney ischemia-reperfusion injury, and providing a new target for preparation of a medicine for preventing and treating acute kidney injury.

The invention belongs to the technical field of medicines, and particularly relates to combined application of a pollen pini aqueous extract and fucoidin in preparation of a medicine for preventing and / or treating renal injury. According to the invention, cell experiment results show that the combination of the pollen pini aqueous extract and the fucoidin has an obvious synergistic effect, the relative activity of HK-2 cells can be obviously improved, the cell apoptosis and ROS level caused by adriamycin can be reduced, and the energy metabolism function of the HK-2 cells can be obviously improved; animal experiment results show that the combination of the pollen pini aqueous extract and the fucoidin can significantly reduce the levels of serum creatinine (Crea), urea nitrogen (Urea) and cystatin C (Cys-C), improve the pathological injury of kidney tissues, relieve the fibrosis process, and provide a theoretical basis and an innovative direction for developing a new strategy for intervention of kidney injury.

The present invention relates to the technical field of pathogen and disease marker detection, and specifically to an ultra-small high-entropy alloy for lateral flow immunochromatography, and its preparation method and application. The preparation method of the high-entropy alloy comprises the following steps: preparing a precursor solution; preparing the high-entropy alloy by a low-temperature reduction-diffusion strategy. The high-entropy alloy prepared by the method of the present invention has excellent catalytic performance and ultra-high peroxidase simulation activity. When applied to lateral flow immunochromatography, it can quickly and accurately detect Staphylococcus aureus, and has the characteristics of high sensitivity and strong specificity. At the same time, the present invention successfully extends the application of the high-entropy alloy to the detection of kidney injury marker cystatin C by modifying the recognition element. The high-entropy alloy for lateral flow immunochromatography provided by the present invention has huge market promotion prospects in the field of pathogen and disease marker detection.

The present application relates to a kind of blood metabolic markers for estimating glomerular filtration rate (GFR) and its application, which includes hydroxy asparagine, and does not include creatinine.The present application successfully identifies new GFR significantly related metabolites by using strict two-center study design, and further determines two new metabolite marker combinations for constructing equations, so that GFR can be reliably estimated without creatinine, cystatin C and population statistics information and clinical feature information (such as race, gender, weight, etc.), and can be used for the development of rapid, convenient and accurate diagnostic kit.

This invention discloses an electrochemical sensor for detecting Cys C, its preparation method, and a method for detecting Cys C. The electrochemical sensor for detecting Cys C includes a working electrode, a reference electrode, and a counter electrode. The working electrode comprises an electrode substrate and nanomaterials and a Cys C aptamer sequentially modified on the electrode substrate. The nanomaterials are MoS2 nanomaterials or gold nanomaterials. The 5′ end of the Cys C aptamer is modified with an electroactive substance X, where X is ferrocene or methylene blue. The 3′ end of the Cys C aptamer is modified with a group Y, where Y is -(CH2). n -SH, where n is a natural number from 1 to 12. The electrochemical sensor of this invention can be used for in vivo quantitative detection of Cys C, and exhibits good performance in terms of cost-effectiveness, ease of operation, and the use of environmentally friendly materials. It is a potential electrochemical sensor for early diagnosis of CKD.

This invention provides a physiological age prediction model that predicts the physiological age of a subject by detecting physical examination indicators. These indicators include measurements of blood cells, glucose metabolism, tumor markers, urine components, anthropometric measurements, lipids, blood components, and tissue function. Preferably, these indicators include one or more selected from the following: glomerular filtration rate (eGFR), cystatin C, serum creatinine (SCr), blood urea nitrogen (BUN), timed up and go, light reaction time, fasting blood glucose (FBG), insulin-like growth factor (IGF), superoxide dismutase (SOD), insulin (INS), albumin (Alb), alkaline phosphatase (ALP), folic acid, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and high-sensitivity C-reactive protein (hs-CRP). More preferably, all of the aforementioned physical examination indicators are included. This invention also provides a physiological age prediction device applying the above-mentioned physiological age prediction model and a computer storage medium.